DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Appendix Neuroendocrine Tumor G1 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAppendix Neuroendocrine Tumor G1 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for appendix neuroendocrine tumor g1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
catenin beta 1 (CTNNB1) — CTNNB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet prodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8Z10 · 2.35 Å · ligand PROLINE (PRO). Experimental structure, not a prediction.
What the evidence adds up to
The largest report on appendiceal neuroendocrine tumours, drawing on 1,021 typical neuroendocrine tumour (TNET) patients from the SEER database between 1973 and 2011, found that TNET presented at a younger age than goblet cell carcinoids (GCC) or signet-ring cell cancers (SRCC). Median overall survival for TNET and GCC was not reached during follow-up, whereas median overall survival for SRCC was 24 months. Multivariate analysis stratified for stage showed significantly longer survival for TNET and GCC than for SRCC. The authors describe these as a spectrum of diseases with different outcomes.
A separate retrospective study of 53 patients with metastatic non-functioning gastroenteropancreatic neuroendocrine tumours, which included appendiceal primaries, compared those who had palliative resection of the primary site with those who did not. Median overall survival was not reached in the resected group, versus 30 months in the unresected group. Median progression-free survival was 60 months in the resected group and 14 months in the unresected group. Unresected primary site and high-grade tumours were independent prognostic factors for lower survival, with hazard ratios of 4.6 and 10.1 respectively. Age, sex, chromogranin A level, Ki-67 index, tumour size, and primary tumour area did not influence overall survival in that analysis.
A 2023 case study describes VIPomas as a subtype of gastroenteropancreatic neuroendocrine tumour that can secrete peptides and cause generalised symptoms, but it does not report any treatment outcomes or survival data for appendix neuroendocrine tumour G1.
No drug treatment is mentioned in any of these abstracts. The evidence for appendix neuroendocrine tumour G1 specifically remains limited to retrospective registry data and single-centre surgical series. What is missing is prospective trial data, any drug intervention tested in this grade and site, and patient stratification by Ki-67 index or tumour size that might clarify which patients benefit from resection versus surveillance.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer Research and Treatment · 2015 · 39 citations · open access
Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome
AbstractPURPOSE: Appendiceal tumors are a heterogeneous group of diseases that include typical neuroendocrine tumors (TNET), goblet cell carcinoids (GCC), and atypical GCC. Atypical GCC are classified into signet-ring cell cancers (SRCC) and poorly differentiated appendiceal adenocarcinoids. The prognosis and management of these diseases is unclear because there are no prospective studies. The aim of this study is to assess the characteristics and outcome of appendiceal TNET, GCC, and SRCC patients. MATERIALS AND METHODS: Appendiceal TNET, GCC, and SRCC patients diagnosed between 1973 and 2011 were identified in the Surveillance Epidemiology and End Results (SEER) database. Demographics, type of surgery, and clinicopathologic characteristics were collected. Survival functions were estimated by the Kaplan-Meier method, and log-rank test was used to assess the difference in overall survival (OS) among the three histologies. RESULTS: The SEER database yielded 1,021 TNET patients, 1,582 with GCC, and 534 SRCC patients. TNET presented at a younger age (p < 0.001). Patients with SRCC presented with advanced stage disease (p < 0.001). The median OS (mOS) for GCC and TNET patients was not reached; mOS for SRCC was 24 months. Multivariate analysis stratified for stage revealed significantly longer survival for TNET and GCC than SRCC (p < 0.001). CONCLUSION: This is the largest report to date for appendiceal neuroendocrine tumor patients, suggesting a spectrum of diseases with different characteristics and outcomes. In this report, we present a treatment approach for this complex spectrum of disease, based on the experience of Ohio State and Emory Universities investigators.
The Turkish Journal of Gastroenterology · 2019 · 4 citations · open access
Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals
AbstractBACKGROUND/AIMS: Gastroenteropancreatic neuroendocrine tumors are rarely seen and have heterogeneous clinical outcomes. Mostly half of the patients had metastatic disease at presentation. Palliative resection of primary site in metastatic disease is still controversial. The aim of this study was to find out the influence of resection of primary tumor site on progression-free survival and overall survival in metastatic non-functioning gastroenteropancreatic neuroendocrine tumors. The secondary end point is to determine the prognostic factors influencing the survivals. MATERIALS AND METHODS: This study was conducted at a single medical oncology center, Antalya Education and Research Hospital. Patients who had non-functioning metastatic gastroenteropancreatic neuroendocrine tumors with primary site resected or unresected were compared retrospectively. Resection of metastases was excluded. RESULTS: Fifty-three patients were included in the study and 29 patients had primary tumor resection. The primary site resected group had favorable outcomes with the overall survival (median unreached) compared to the median overall survival of 30 months in the unresected group (p=0.001). Median progression-free survival was also better in the primary site resected group than the unresected group (60 months vs. 14 months, respectively) (p=0.013). In multivariate analysis, unresected primary site and high-grade tumors were found to be independent prognostic factors on low survivals (Hazard ratio (HR): 4.6; 95% CI: 1.21-17.47 and HR: 10.1; 95% CI: 1.15-88.84, respectively). Age (p=0.131), gender (p=0.051), chromogranin A level (p=0.104), Ki-67 index (p=0.550), tumor size (p=0.623), and primary tumor area (p=0.154) did not influence the overall survival. CONCLUSION: Gastroenteropancreatic neuroendocrine tumors with primary site resected had improved survivals when compared to the unresected group.
Journal of Clinical Images and Medical Case Reports · 2023 · 0 citations · open access
A case study of the multifaceted therapeutic approach of VIPomas
AbstractNeuroendocrine tumors, arising from neuroendocrine cells, a group of malignant tumors capable of secreting peptides and biogenic amines, are differentiated as either diffuse endocrine system (DES) or gastroentero-pancreatic neuroendocrine tumors (GEP-NET). The latter are rare tumors that synthesize various substances, leading to the onset of certain generalized symptoms
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
